Sona's test excellent! Executive Summary
To assist in containing the spread of the SARS-CoV-2 virus, it is now globally recognised that rapid antigen
tests (RDT’s) have an important role to play in identifying undiscovered cases that would typically be
missed if a rapid testing strategy were not put in place.
Sona’s COVID-19 LFA rapid antigen test is set to play a major role is this battle. A recent clinical evaluation
demonstrated that this test identified the presence of the SARS-CoV-2 virus in 33 of 39 RT-PCR positive
patient samples (Sensitivity; 85%) and ruled out its presence in 54 of 60 negative RT-PCR patient samples
(Specificity 90%).
Infection within 0-8 days of symptom onset and/or low Ct counts have both been associated with an
increased risk of infectiousness of COVID-19. An increase in test sensitivity in these patient subgroups was
observed. The Sona LFA identified 17/18 RT-PCR positive patient samplesthat presented symptoms within
0-8 days (94% Sensitivity) and 9/9 RT-PCR positive patients with low Ct counts (<25) (100% sensitivity)
These findings provide evidence that the Sona COVID-19 rapid antigen test can be a useful aid in screening
programmes to identify subjects with a high risk of transmission of clinical COVID-19.